· Inhibits the survival pathway of autophagy by preventing the degradation of autophagosomes, resulting in increased apoptosis of human CD4+CD45RO+ memory and effector T cells (van Loosdregt et al.).
· In combination with various other treatments, increases the overall response rate, progression-free survival, and 1-year overall survival rate of cancer therapies (for glioblastoma, brain metastases due to non-small-cell lung cancer and breast cancer, pancreatic ductal adenocarcinoma [PDAC], non-Hodgkin lymphoma, metastatic PDAC, and pancreatic cancer), when compared to cancer therapies that do not utilize autophagy inhibition (Xu et al.).
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.